The effect of borneol on the concentration of meropenem in rat brain and blood

Hai-li, Xin; He, Xinrong; Li, Wei; Zhou, Zhengyuan; Zhang, Shuo; Wang, Guanjun

doi:10.1080/10286020.2014.916282

Cited by 8 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar region-specific enhancement by borneol was also observed for puerarin and edaravone in the cortex (Gao et al, 2010), kaempferol in the hippocampus , meropenem in the striatum (Xin et al, 2014) and ligustrazine in the hypothalamus and the striatum (Yu et al, 2016). This may be directly associated with the brain region-specific distribution of borneol, suggesting that borneol's enhancement of CNS drug delivery varies in different brain regions.…”

Section: Brain-regional Specificity Of the Improvement In Cns Drug Dementioning

confidence: 59%

Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability

Zhang

2017

Drug Delivery

135

View full text Add to dashboard Cite

The clinical application of central nervous system (CNS) drugs is limited by their poor bioavailability due to the blood-brain barrier (BBB). Borneol is a naturally occurring compound in a class of 'orificeopening' agents often used for resuscitative purposes in traditional Chinese medicine. A growing body of evidence confirms that the 'orifice-opening' effect of borneol is principally derived from opening the BBB. Borneol is therefore believed to be an effective adjuvant that can improve drug delivery to the brain. The purpose of this paper is to provide a comprehensive review of information accumulated over the past two decades on borneol's chemical features, sources, toxic and kinetic profiles, enhancing effects on BBB permeability and their putative mechanisms, improvements in CNS drug delivery, and pharmaceutical forms. The BBB-opening effect of borneol is a reversible physiological process characterized by rapid and transient penetration of the BBB and highly specific brain regional distribution. Borneol also protects the structural integrity of the BBB against pathological damage. The enhancement of the BBB permeability is associated with the modulation of multiple ATP-binding cassette transporters, including P-glycoprotein; tight junction proteins; and predominant enhancement of vasodilatory neurotransmitters. Systemic co-administration with borneol improves drug delivery to the brain in a region-, dose-and time-dependent manner. Several pharmaceutical forms of borneol have been developed to improve the kinetic and toxic profiles of co-administered drugs and enhance their delivery to the brain. Borneol is a promising novel agent that deserves further development as a BBB permeation enhancer for CNS drug delivery. ARTICLE HISTORY

show abstract

Section: Brain-regional Specificity Of the Improvement In Cns Drug Dementioning

confidence: 59%

Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability

Zhang

2017

Drug Delivery

135

View full text Add to dashboard Cite

show abstract

“…Of which, 18 studies were lack of outcome assessments for BBB integrity, 67 studies did not test on co-administration of drug concentrations in CNS and/or the safety of borneol and/or the various indexes of BBB permeability, 2 studies compared with medicine or another agent with potential similar effect, 2 studies were lack of control group, 10 studies were in vitro studies, and 13 studies were duplicate publications. Ultimately, 58 studies (Wang et al., 1992 ; Liang et al., 1993 ; Liu et al., 1994 ; Xu & Wang, 1995 ; Dong et al., 2002 ; Lin et al., 2003 ; Jia et al., 2004 ; Wu et al., 2004 ; Zhang et al., 2005 ; Chen, 2005 ; Zhou et al., 2005 ; Wang, 2006 ; Wang et al., 2006 ; Zheng et al., 2007 ; Xiao et al., 2007 ; Chen et al., 2007 ; Zhang et al., 2007 ; Liu & Gao, 2007 ; Lin et al., 2008 ; Liu et al., 2016 ; Zhou et al., 2008 ; Shi & Zhao, 2008 ; Li et al., 2008 ; Liu et al., 2008 ; Ge et al., 2008 ; Gao et al., 2009 ; Wu et al., 2009 ; Wang et al., 2009 ; Xiao & Ping, 2009 ; Chai et al., 2009 ; Zhu, 2009 ; Wei et al., 2010 ; Zhang, 2011 ; Wu, 2011 ; Zhang et al., 2011 ; Wang et al., 2011 ; Yu et al., 2011 ; Wu et al., 2011 ; Dong et al., 2012 ; Yu et al., 2012 ; Wang et al., 2012 ; Cao, 2013 ; Yu et al., 2013 ; Diao et al., 2013 ; Huang et al., 2013 ; Zhang, 2014 ; Xin et al., 2014 ; Liu, 2015 ; Zhang et al., 2015 ; Guo et al.,…”

Section: Resultsmentioning

confidence: 99%

Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood–brain barrier permeability: a preclinical systematic review and meta-analysis

Zheng

Chen

et al. 2018

Drug Delivery

View full text Add to dashboard Cite

To achieve sufficient blood–brain barrier (BBB), penetration is one of the biggest challenges in the development of diagnostic and therapeutic for central nervous system (CNS) disorders. Here, we conducted a systematic review and meta-analysis to assess the preclinical evidence and possible mechanisms of borneol for improving co-administration of CNS drug delivery in animal models. The electronic literature search was conducted in six databases. Fifty-eight studies with 63 comparisons involved 1137 animals were included. Among 47 studies reporting the assessments of CNS drug concentration, 45 studies showed the significant effects of borneol for improving CNS drug delivery (p<.05), whereas 2 studies showed no difference (p>.05). Nineteen comparisons showed borneol up-regulated BBB permeability (p<.05) using brain EB content (n = 8), Rh 123 content (n = 4), brain imaging agent content (n = 2), brain water content (n = 1) and observing ultrastructure of BBB (n = 4), whereas three studies showed no difference or unclear results. Seven studies reported the safety, in which one study showed borneol was reversible changes in the BBB penetration; six studies showed borneol did not increase co-administration of blood drugs concentration of peripheral tissues (p > .05). Effects of borneol are closely associated with inhibition of efflux protein function, releasement of tight junction protein, increasement of vasodilatory neurotransmitters, and inhibition of active transport by ion channels. In conclusion, borneol is a promising candidate for CNS drug delivery, mainly through mediating a multi-targeted BBB permeability.

show abstract

“…Recent studies showed that borneol could promote penetration of methotrexate, nimustine, and other drugs through the BBB, increasing drug concentration in the brain. 5 The purpose of this study is to further elucidate the role of borneol in the opening of the BBB and delineate the underlying molecular mechanism.…”

Section: Introductionmentioning

confidence: 99%

The Role and Mechanism of Borneol to Open the Blood-Brain Barrier

Zhang

et al. 2018

Integr Cancer Ther

View full text Add to dashboard Cite

Background: The blood-brain barrier (BBB) is the greatest challenge in the treatment of intracranial malignant tumors. Objective: The aim of this study is to determine the role of borneol in opening the BBB and elucidate the underlying mechanisms. Materials and Methods: Twenty Sprague-Dawley (SD) rats were randomized into borneol group intragastrically administered with 10% borneol corn oil (2 mL/kg) and control group. After 30 minutes, 2% Evans blue (4 mL/kg) was injected. Thirty minutes later, brain tissue was analyzed using the Evans blue standard curve. Another 40 SD rats were randomized into high-, medium-, and low-dose borneol groups and a control group. Each rat in the experimental groups was intragastrically administered with 10% borneol corn oil (2 mL/kg, 1.25 mL/kg, and 0.5 mL/kg, respectively). The control group was injected with corn oil of 1.25 mL/kg. After 30 minutes, the rats were killed, and the brain tissues were collected. The expression of occludin, occludens-1, nitric oxide synthase, P-glycoprotein, and intercellular cell adhesion molecule-1 (ICAM-1) was detected by immunohistochemy. Results: The concentration of Evans blue in the borneol group was higher than in the control group (P < .05). The mean density of ICAM-1 expression was higher in the experimental group than in the control group (P < .05). In contrast, significant differences of positive area and total density of ICAM-1 were shown only between the high-dose group and the control group (P < .05). Conclusion: Borneol can open the BBB, which might be related with the increased expression of ICAM-1.

show abstract

The effect of borneol on the concentration of meropenem in rat brain and blood

Cited by 8 publications

References 5 publications

Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability

Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability

Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood–brain barrier permeability: a preclinical systematic review and meta-analysis

The Role and Mechanism of Borneol to Open the Blood-Brain Barrier

Contact Info

Product

Resources

About